Piedmont Investment Advisors LLC boosted its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 83,285 shares of the medical research company’s stock after buying an additional 707 shares during the period. Piedmont Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $12,793,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. Washington Trust Bank boosted its position in Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock valued at $339,000 after buying an additional 10 shares in the last quarter. Cullinan Associates Inc. boosted its position in Thermo Fisher Scientific by 24.0% in the first quarter. Cullinan Associates Inc. now owns 28,380 shares of the medical research company’s stock valued at $4,359,000 after buying an additional 5,500 shares in the last quarter. American Research & Management Co. boosted its position in Thermo Fisher Scientific by 7.7% in the first quarter. American Research & Management Co. now owns 2,790 shares of the medical research company’s stock valued at $429,000 after buying an additional 200 shares in the last quarter. Graybill Bartz & Assoc Ltd. boosted its position in Thermo Fisher Scientific by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 20,120 shares of the medical research company’s stock valued at $3,090,000 after buying an additional 295 shares in the last quarter. Finally, Tompkins Financial Corp boosted its position in Thermo Fisher Scientific by 0.8% in the first quarter. Tompkins Financial Corp now owns 5,183 shares of the medical research company’s stock valued at $733,000 after buying an additional 40 shares in the last quarter. Institutional investors and hedge funds own 87.60% of the company’s stock.
Thermo Fisher Scientific Inc (NYSE TMO) traded up 1.20% during midday trading on Wednesday, hitting $175.65. The stock had a trading volume of 487,101 shares. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $182.87. The stock has a market capitalization of $68.52 billion, a price-to-earnings ratio of 30.60 and a beta of 1.06. The company’s 50 day moving average price is $176.78 and its 200-day moving average price is $166.23.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same quarter in the prior year, the company earned $2.03 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.35%. Thermo Fisher Scientific’s payout ratio is 10.45%.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/16/piedmont-investment-advisors-llc-purchases-707-shares-of-thermo-fisher-scientific-inc-tmo.html.
Several equities analysts recently issued reports on the company. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Barclays PLC reiterated an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Wells Fargo & Company reiterated an “outperform” rating and issued a $200.00 price target (up previously from $195.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 13th. Finally, Citigroup Inc. restated a “buy” rating and set a $201.00 target price (up previously from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $188.56.
In related news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now owns 269,279 shares in the company, valued at approximately $46,528,718.41. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel P. Shine sold 4,688 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total value of $805,773.44. Following the sale, the insider now owns 29,200 shares in the company, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,188 shares of company stock worth $4,702,223. 0.49% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.
